Amicus Therapeutics (FOLD) to Release Quarterly Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect Amicus Therapeutics to post earnings of $0.01 per share and revenue of $146.68 million for the quarter.

Amicus Therapeutics Trading Down 0.5%

Amicus Therapeutics stock traded down $0.03 during mid-day trading on Thursday, hitting $6.28. The stock had a trading volume of 3,081,970 shares, compared to its average volume of 4,158,104. The stock has a market capitalization of $1.93 billion, a PE ratio of -69.77 and a beta of 0.51. The stock has a 50-day simple moving average of $6.08 and a two-hundred day simple moving average of $7.60. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $12.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its holdings in Amicus Therapeutics by 7.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company's stock valued at $22,061,000 after purchasing an additional 194,213 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Amicus Therapeutics by 11.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company's stock worth $8,751,000 after acquiring an additional 113,803 shares during the period. Intech Investment Management LLC lifted its holdings in Amicus Therapeutics by 37.1% during the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company's stock worth $1,395,000 after acquiring an additional 46,218 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Amicus Therapeutics during the first quarter worth about $30,000.

Wall Street Analyst Weigh In

A number of research firms recently commented on FOLD. Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. UBS Group boosted their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley upgraded Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Finally, The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.